diabetes

On this episode, Dr. Lisa Iezzoni joins our host, Dr. Joe Sirven, to examine the responsibilities of four-legged health care professionals.

New research shows that the number of 12- to 25-year-olds who used the GLP-1 medications climbed from about 8,700 a month in 2020 to 60,000 a month in 2023.

The makers of Ozempic and Mounjaro charge charge around $1,000 a month for the drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.

Host Dr. Joe Sirven and guests identify signs and symptoms of stroke, stroke treatment and lifestyle factors that contribute to the risk of a brain attack.

Studies suggest people who take metformin for diabetes may be at lower risk for cancer, heart disease and dementia. Now researchers aim to test if it prevents age-related diseases in healthy people.

The European Medicines Agency regulatory committee joins the FDA in saying there's no known tie between the semaglutide obesity drugs and suicide.

With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.

The FDA granted a request for a qualified health claim from Danone North America. Such claims lack full scientific support but are allowed as long as they include disclaimers.

Adults who develop one autoimmune form of diabetes are often misdiagnosed with Type 2. Those wrong diagnoses make it harder to get the appropriate medications and technology to manage blood sugar.

Last January, Anderson Ata became the seventh person in the world to receive teplizumab, which researchers say is the first big milestone in treating diabetes since the production of insulin over 100 years ago.